Clinical Trial Update: C3G/Primary IC-MPGN EAP

View source ↗

Summary

Apellis' pegylated C3 inhibitor pegcetacoplan has gained marketing approval for C3 glomerulopathy and immune complex–mediated MPGN as part of the C3G/IC-MPGN pr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• C3 Glomerulopathy
• Dense Deposit Disease
• Immune Complex-mediated Membranoproliferative Glomerulonephritis
• Membranoproliferative Glomerulonephritis

Drugs mentioned

• EMPAVELI (pegcetacoplan)

Snippet

Sponsor: Apellis Pharmaceuticals, Inc. | Conditions: C3G, IC-MPGN | Status: APPROVED_FOR_MARKETING